Jubilant Ingrevia Limited (Formerly known as Jubilant LSI Limited) was incorporated as a Public Limited Company on October 23, 2019, in Uttar Pradesh. The name of the Company was changed from Jubilant LSI Limited to Jubilant Ingrevia Limited on October 16, 2020. Listing date: March 19, 2021, and Chairperson Name: Shyam S Bhartia. Managing Director & CEO: Mr. Deepak Jain.
The Company is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customized products and solutions that are innovative, cost-effective, and conforming to excellent quality standards. Ingrevia is born out of a union of 'Ingredients' and 'Life' ("Vie" in French). Jubilant is committed to Protect, Enhance, and Advance all forms of life – human, animal, and plant, by offering high quality and innovative life science ingredients.
With over 40+ years of legacy in Chemicals space, started in 1978 and is a part of the Jubilant Bhartia Group, a diversified global conglomerate. Jubilant Ingrevia was founded in 2019. Jubilant Ingrevia is headquartered in Noida, India.
Jubilant Ingrevia operates through three primary business segments that cater to diverse industries and applications:
It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. As of 2022, Jubilant Ingrevia is the world's lowest cost producer of pyridine-based derivative products, one of the two producers of pyridine, and a leader in 14 pyridine derivatives. Jubilant Ingrevia also offers contract development and manufacturing (CDMO) services to international innovator pharmaceutical and agrochemical companies.
Nutrition & Health Solutions caters to Human & Animal Nutrition, Pharmaceutical & Personal Care segment/applications. It consists of three businesses - Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, and Human Nutrition & Health Solutions. The company is one of the two largest manufacturers of vitamin B3 globally, one of India's largest manufactures of vitamin B4.
Chemical Intermediates manufactures a range of Chemical Intermediates which includes Acetyl Products and Specialty Ethanol. Its segments are Specialty Chemicals, Nutrition, and Health Solutions, and Chemical Intermediates. The maximum revenue for the company is generated from its Chemical Intermediates segment, which manufactures acetyls, and specialty ethanol. It is one of the two largest producers of acetic anhydride, and a large producer of ethyl acetate.
Jubilant Ingrevia Limited is supported by five state-of-the-art manufacturing facilities in India. The Company has five manufacturing facilities in India and specializes in the production of nutritional ingredients, specialty chemicals, nutrition and health solutions, and life science chemicals. It caters to more than 1,400 customers in over 60 countries, making it a partner of choice for over 400 global customers.
The Company offers over 125 products & innovative solutions using more than 35 key chemistry and technology platforms across its three business segments of Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Company is driven by the motive to add value to millions of lives through innovations and cutting-edge technology. It's over 2,100 employees serve over 1,500 customers in more than 50 countries across the world.
Revenue: ₹1,038.16 Crore as on March 2025 (Q4 FY25). Net Profit: ₹74.05 Crore as on March 2025 (Q4 FY25). For the full year, net profit rose 37.33% to ₹251.17 Crore in the year ended March 2025, as against ₹182.89 Crore during the previous year ended March 2024. Sales rose 0.57% to ₹4,123.67 Crore in the year ended March 2025, as against ₹4,100.45 Crore during the previous year ended March 2024.
- Market Cap: ₹12,455 Crore.
- Jubilant Ingrevia Ltd's net profit jumped 153.16% since last year same period to ₹74.05 Crore in Q4 FY2024-2025.
- In the quarter ending December 2024, Jubilant Ingrevia Ltd declared a dividend of ₹2.50, translating to a dividend yield of 1.08%.
Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies. Leading Low-Cost provider. Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
The company has been actively expanding its manufacturing capabilities and entering into strategic partnerships. It commissioned the 25,000 TPA New Acetic Anhydride Plant in Bharuch, Gujarat. The Company launched new products by introducing the foodgrade Choline Chloride and Choline Bitartrate in FY24. Further, a new agrochemical plant at SEZ Bharuch commissioned in FY 2024.
The contract comes one year after carrying out the same exercise at its manufacturing facilities in Savli, Gujarat and Gajraula, Uttar Pradesh for which supply is scheduled to begin in April 2025. With the signing of this contract over 35% of Jubilant Ingrevia's over-all energy requirement at all manufacturing facilities will be met through renewable energy.
66.67% of analysts recommend a 'BUY' rating for Jubilant Ingrevia Ltd. Average target price of ₹917.67 and Jubilant Ingrevia Ltd target price ₹917.67, a slight upside of 29.8% compared to current price of ₹694, according to 3 analyst ratings.
Promoter holding in Jubilant Ingrevia Ltd has remained stable at 51.48% as of March 2025 (unchanged from June 2024).
The company's strong market position, diverse product portfolio, and strategic focus on innovation and sustainability continue to drive its growth trajectory across global markets. With its established manufacturing capabilities and strong customer relationships, Jubilant Ingrevia remains well-positioned to capitalize on the growing demand for life science ingredients and specialty chemicals worldwide.
